Market Cap 691.95M
Revenue (ttm) 311.71M
Net Income (ttm) 163.06M
EPS (ttm) N/A
PE Ratio 4.67
Forward PE 16.80
Profit Margin 52.31%
Debt to Equity Ratio 0.00
Volume 1,382,400
Avg Vol 1,280,086
Day's Range N/A - N/A
Shares Out 78.45M
Stochastic %K 0%
Beta 1.46
Analysts Strong Sell
Price Target $15.00

Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was in...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 517 9500
Address:
389 Interpace Pkwy, Suite 450, Parsippany, United States
VictoryFormation
VictoryFormation Jun. 25 at 3:36 AM
$CRMD Scum suckers
0 · Reply
Noname2022
Noname2022 Jun. 25 at 1:28 AM
0 · Reply
Noname2022
Noname2022 Jun. 25 at 12:00 AM
$CRMD $DVA Davita will bank 10’s of millions per year for not adopting Defencath…hope that changes soon…
4 · Reply
Sahil1991
Sahil1991 Jun. 24 at 11:47 PM
$CRMD The other point from the proposed rule document is that we got some updated projections on how much the total add-on payments will cost in 2027 of $170M (around 5x 2026 $34M). Hopefully now the CBO score can be completed using updated and CMS validated projects and KCAPA can progress further. Note that they estimated TDAPA (not add-on) spend in 2026 would be $500M, and it was $430M (confirmed in today's proposed rule rule). No idea if this helps KCAPA or not. But also sick of getting lost in the TDAPA, CMS, rule-making, add-on calc, etc labrynth. Joe executes. This management team are way ahead of today's announcement. They know the CMS cannot be relied upon to make the changes needed, and it comes down to their execution in contracting with customers and optimising manufacturing. That's why Joe emphasises that - in the near-term - DefenCath comes down to 3 customer relationships (so management aren't spread too thin!)
1 · Reply
gorditacrunchbis
gorditacrunchbis Jun. 24 at 11:46 PM
$CRMD Trending :O
0 · Reply
JackNapier22
JackNapier22 Jun. 24 at 11:30 PM
$CRMD people holding this while stocks like MU go up 700% in a year. amazing.
0 · Reply
Sahil1991
Sahil1991 Jun. 24 at 11:30 PM
$CRMD Might be wishful thinking, but I don't think the add-on payment is THAT important (especially when it's a single digit number). My understanding is that operators receive this whether or not they use DefenCath. Add-on or no add-on, CRMD have to SELL operators that DefenCath is worth buying (which it is) & agree a price. They have to maintain good relationships with the 3 biggest customers (~90% sales) and appear to have contracts in the bag, a movement towards SoC, and independent customer validation. So it looks good here, & maybe Joe can announce DO contracts with certainty now, but maybe it's a wait for final rule. Of course, the add-on may figure in negotiations or act as a discount for the operator, but the add-on is not tied to DefenCath usage in a concrete enough way to truly matter. H2 26 will show how serious customers are about DefenCath and simultaneously demonstrate that the add-on makes no difference to their thinking. The add-on is a nice to have, but not necessary.
1 · Reply
S2730
S2730 Jun. 24 at 11:01 PM
$CRMD Cool. Now we’re down 2% and trending thanks to 50 mundane posts about nothing.
1 · Reply
Andy1063
Andy1063 Jun. 24 at 10:56 PM
$CRMD Decent chance our number will go up on the final rule....
0 · Reply
Noname2022
Noname2022 Jun. 24 at 10:54 PM
$CRMD 80% of patients don’t use Defencath! Do’s get reimbursed per session not utilization. So roughly 5 sessions pay for the one customer needing Defencath (~$20/vial at run rate maybe; 2 vials per session)
0 · Reply
Latest News on CRMD
CorMedix Transcript: AGM 2026

Jun 23, 2026, 9:00 AM EDT - 1 day ago

CorMedix Transcript: AGM 2026


CorMedix Slides: Corporate presentation

May 22, 2026, 7:00 AM EDT - 4 weeks ago

CorMedix Slides: Corporate presentation


CorMedix Earnings Call Transcript: Q1 2026

May 14, 2026, 8:30 AM EDT - 5 weeks ago

CorMedix Earnings Call Transcript: Q1 2026


CorMedix Earnings release: Q1 2026

May 14, 2026, 8:30 AM EDT - 5 weeks ago

CorMedix Earnings release: Q1 2026


CorMedix Quarterly report: Q1 2026

May 14, 2026, 8:30 AM EDT - 5 weeks ago

CorMedix Quarterly report: Q1 2026


CorMedix reports Q1 EPS 43c, consensus 33c

2026-05-14T11:53:51.000Z - 5 weeks ago

CorMedix reports Q1 EPS 43c, consensus 33c


CorMedix Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

CorMedix Proxy statement: Proxy filing


CorMedix Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

CorMedix Proxy statement: Proxy filing


CorMedix price target raised to $14 from $13 at RBC Capital

2026-04-28T11:56:23.000Z - 2 months ago

CorMedix price target raised to $14 from $13 at RBC Capital


CorMedix announces ReSPECT clinical trial met primary endpoint

2026-04-27T12:05:37.000Z - 2 months ago

CorMedix announces ReSPECT clinical trial met primary endpoint


CorMedix Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

CorMedix Proxy statement: Proxy filing


CorMedix Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 9:35 AM EDT - 3 months ago

CorMedix Transcript: The Citizens Life Sciences Conference 2026


CorMedix Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 1:00 PM EDT - 3 months ago

CorMedix Transcript: Leerink Global Healthcare Conference 2026


CorMedix Slides: Corporate presentation

Mar 7, 2026, 6:00 AM EST - 3 months ago

CorMedix Slides: Corporate presentation


CorMedix price target lowered to $13 from $15 at Leerink

2026-03-06T17:05:52.000Z - 3 months ago

CorMedix price target lowered to $13 from $15 at Leerink


CorMedix Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 3 months ago

CorMedix Earnings Call Transcript: Q4 2025


CorMedix Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 3 months ago

CorMedix Annual report: Q4 2025


CorMedix Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 3 months ago

CorMedix Earnings release: Q4 2025


CorMedix reports Q4 EPS 16c vs 20c last year

2026-03-05T12:36:24.000Z - 3 months ago

CorMedix reports Q4 EPS 16c vs 20c last year


CorMedix to Participate in Upcoming Investor Conferences

Feb 12, 2026, 8:30 AM EST - 4 months ago

CorMedix to Participate in Upcoming Investor Conferences


CorMedix Transcript: Investor Day 2026

Feb 10, 2026, 1:00 PM EST - 4 months ago

CorMedix Transcript: Investor Day 2026


CorMedix Slides: FY 2026

Feb 10, 2026, 1:00 PM EST - 4 months ago

CorMedix Slides: FY 2026


CorMedix Therapeutics Announces Share Repurchase Program

Feb 2, 2026, 8:30 AM EST - 5 months ago

CorMedix Therapeutics Announces Share Repurchase Program


CorMedix price target lowered to $13 from $22 at RBC Capital

2026-01-21T11:35:46.000Z - 5 months ago

CorMedix price target lowered to $13 from $22 at RBC Capital


CorMedix Slides: Corporate presentation

Jan 10, 2026, 7:00 AM EST - 5 months ago

CorMedix Slides: Corporate presentation


CorMedix price target lowered to $16 from $20 at Truist

2026-01-08T17:45:22.000Z - 5 months ago

CorMedix price target lowered to $16 from $20 at Truist


CorMedix sees FY26 revenue $300M-$320M

2026-01-08T13:17:12.000Z - 5 months ago

CorMedix sees FY26 revenue $300M-$320M


CorMedix Therapeutics Announces Leadership and Board Updates

Jan 8, 2026, 8:05 AM EST - 5 months ago

CorMedix Therapeutics Announces Leadership and Board Updates


CorMedix Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

CorMedix Earnings Call Transcript: Q3 2025


CorMedix Quarterly report: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

CorMedix Quarterly report: Q3 2025


CorMedix Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

CorMedix Earnings release: Q3 2025


CorMedix Proxy statement: Proxy Filing

Oct 24, 2025, 8:00 AM EDT - 8 months ago

CorMedix Proxy statement: Proxy Filing


CorMedix Proxy statement: Proxy Filing

Oct 14, 2025, 8:00 AM EDT - 9 months ago

CorMedix Proxy statement: Proxy Filing


CorMedix Registration statement: Registration Filing

Sep 30, 2025, 8:00 AM EDT - 9 months ago

CorMedix Registration statement: Registration Filing


CorMedix Proxy statement: Proxy Filing

Sep 15, 2025, 8:00 AM EDT - 10 months ago

CorMedix Proxy statement: Proxy Filing


CorMedix Announces Strategic Minority Investment in Talphera

Sep 8, 2025, 8:30 AM EDT - 10 months ago

CorMedix Announces Strategic Minority Investment in Talphera

TLPH


CorMedix Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 8:35 AM EDT - 10 months ago

CorMedix Transcript: Cantor Global Healthcare Conference 2025


CorMedix to Buy Melinta Therapeutics for $300 Million

Aug 7, 2025, 10:49 AM EDT - 11 months ago

CorMedix to Buy Melinta Therapeutics for $300 Million


CorMedix Quarterly report: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 11 months ago

CorMedix Quarterly report: Q2 2025


CorMedix Earnings release: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 11 months ago

CorMedix Earnings release: Q2 2025


CorMedix inc. Announces Customer Implementation

Jun 23, 2025, 7:30 AM EDT - 1 year ago

CorMedix inc. Announces Customer Implementation


CorMedix Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Earnings Call Transcript: Q1 2025


CorMedix Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Quarterly report: Q1 2025


CorMedix Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

CorMedix Earnings release: Q1 2025


CorMedix Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CorMedix Proxy statement: Proxy Filing


CorMedix Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

CorMedix Proxy statement: Proxy Filing


VictoryFormation
VictoryFormation Jun. 25 at 3:36 AM
$CRMD Scum suckers
0 · Reply
Noname2022
Noname2022 Jun. 25 at 1:28 AM
0 · Reply
Noname2022
Noname2022 Jun. 25 at 12:00 AM
$CRMD $DVA Davita will bank 10’s of millions per year for not adopting Defencath…hope that changes soon…
4 · Reply
Sahil1991
Sahil1991 Jun. 24 at 11:47 PM
$CRMD The other point from the proposed rule document is that we got some updated projections on how much the total add-on payments will cost in 2027 of $170M (around 5x 2026 $34M). Hopefully now the CBO score can be completed using updated and CMS validated projects and KCAPA can progress further. Note that they estimated TDAPA (not add-on) spend in 2026 would be $500M, and it was $430M (confirmed in today's proposed rule rule). No idea if this helps KCAPA or not. But also sick of getting lost in the TDAPA, CMS, rule-making, add-on calc, etc labrynth. Joe executes. This management team are way ahead of today's announcement. They know the CMS cannot be relied upon to make the changes needed, and it comes down to their execution in contracting with customers and optimising manufacturing. That's why Joe emphasises that - in the near-term - DefenCath comes down to 3 customer relationships (so management aren't spread too thin!)
1 · Reply
gorditacrunchbis
gorditacrunchbis Jun. 24 at 11:46 PM
$CRMD Trending :O
0 · Reply
JackNapier22
JackNapier22 Jun. 24 at 11:30 PM
$CRMD people holding this while stocks like MU go up 700% in a year. amazing.
0 · Reply
Sahil1991
Sahil1991 Jun. 24 at 11:30 PM
$CRMD Might be wishful thinking, but I don't think the add-on payment is THAT important (especially when it's a single digit number). My understanding is that operators receive this whether or not they use DefenCath. Add-on or no add-on, CRMD have to SELL operators that DefenCath is worth buying (which it is) & agree a price. They have to maintain good relationships with the 3 biggest customers (~90% sales) and appear to have contracts in the bag, a movement towards SoC, and independent customer validation. So it looks good here, & maybe Joe can announce DO contracts with certainty now, but maybe it's a wait for final rule. Of course, the add-on may figure in negotiations or act as a discount for the operator, but the add-on is not tied to DefenCath usage in a concrete enough way to truly matter. H2 26 will show how serious customers are about DefenCath and simultaneously demonstrate that the add-on makes no difference to their thinking. The add-on is a nice to have, but not necessary.
1 · Reply
S2730
S2730 Jun. 24 at 11:01 PM
$CRMD Cool. Now we’re down 2% and trending thanks to 50 mundane posts about nothing.
1 · Reply
Andy1063
Andy1063 Jun. 24 at 10:56 PM
$CRMD Decent chance our number will go up on the final rule....
0 · Reply
Noname2022
Noname2022 Jun. 24 at 10:54 PM
$CRMD 80% of patients don’t use Defencath! Do’s get reimbursed per session not utilization. So roughly 5 sessions pay for the one customer needing Defencath (~$20/vial at run rate maybe; 2 vials per session)
0 · Reply
Noname2022
Noname2022 Jun. 24 at 10:43 PM
2 · Reply
Noname2022
Noname2022 Jun. 24 at 10:31 PM
$CRMD The Defencath add on was calculated based on this time line: January 1, 2025 through December 31, 2025 Q1 2025: $39.1M Q2 2025: ~$31.0M Q3 2025: $88.8M Q4 2025: $91.2M The add on payment should revise upward quarterly once Q1 & Q2 2026 are taken into account
0 · Reply
Noname2022
Noname2022 Jun. 24 at 10:16 PM
$CRMD They are proposing quarterly TDAPA updates! https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2027-end-stage-renal-disease-esrd-prospective-payment-system-proposed-rule
0 · Reply
REZZAYO
REZZAYO Jun. 24 at 10:13 PM
$CRMD — Annual Meeting Voting Results Elliott’s ownership has reduced from roughly 21% in 2020 to about 0.63% today. Their era of automatic board support is over. especially for directors with weak support and a history tied to selling pressure “Janet Dillione” Say-on-pay passed, but weakly. Exclusive Forum failed. Message: execute first — DaVita, MA contracts, KCAPA, REZZAYO growth — then ask afterwards. Proposals 4, 5, and 7 likely failed because shareholders will not grant more flexibility while the stock remains undervalued. Class Voting failed for one simple reason: shareholders want control to stay with shareholders.
0 · Reply
Noname2022
Noname2022 Jun. 24 at 10:07 PM
$CRMD $AKBA https://public-inspection.federalregister.gov/2026-12925.pdf
3 · Reply
Noname2022
Noname2022 Jun. 24 at 10:02 PM
$CRMD https://www.bennet.senate.gov/2026/06/24/bennet-young-colleagues-reintroduce-bipartisan-pasteur-act-to-fight-antimicrobial-resistance/
1 · Reply
Gencooliveoil
Gencooliveoil Jun. 24 at 9:42 PM
$CRMD Following a strong first-quarter earnings beat, CorMedix updated its full-year guidance for 2026:Net Revenue: Projected between $325 million and $345 million (raised from the initial $300 million to $320 million forecast).Adjusted EBITDA: Projected between $115 million and $135 million.Key Growth Drivers: Continued high utilization of the outpatient dialysis product DefenCath along with the acquired Melinta portfolio. Bullish
0 · Reply
Gencooliveoil
Gencooliveoil Jun. 24 at 9:41 PM
$CRMD Vanguard's CRMD Holdings OverviewVanguard Position Size: Vanguard and its affiliates own approximately 4.5+ million shares across various funds, representing around 4-5% of the total outstanding stock.Primary Vanguard ETFs holding CRMD: The Vanguard Total Stock Market ETF (VTI) is the largest single Vanguard ETF holder of CRMD, utilizing the stock to provide broad exposure across the U.S. micro- and small-cap segments.Other Vanguard Funds: CRMD is also held in specialized or extended market ETFs, such as the Vanguard Extended Market ETF (VXF).
0 · Reply
Gencooliveoil
Gencooliveoil Jun. 24 at 9:39 PM
$CRMD BlackRock, Inc. holds a 7.31% to 7.61% institutional ownership stake in CorMedix Inc. (NASDAQ:CRMD), managing a position of roughly 5.96 million shares valued at approximately $40 to $52 million. They are consistently the second-largest institutional shareholder behind Deep Track Capital.BlackRock's exact position details are broken down below:Shares Held: 5,967,575 sharesPosition Value: ~$52.3 millionOwnership Percentage: ~7.61% of outstanding CRMD sharesLatest Filing: BlackRock reported a 3.31% share increase in their latest 13F filing period
0 · Reply
Gencooliveoil
Gencooliveoil Jun. 24 at 9:03 PM
0 · Reply
Gencooliveoil
Gencooliveoil Jun. 24 at 9:03 PM
0 · Reply
Gencooliveoil
Gencooliveoil Jun. 24 at 9:03 PM
0 · Reply